Journal ArticleDOI
Biological Processing of DNA Modified by Platinum Compounds
Reads0
Chats0
About:
This article is published in ChemInform.The article was published on 1991-10-01. It has received 63 citations till now. The article focuses on the topics: Nucleic acid.read more
Citations
More filters
Journal ArticleDOI
Mechanisms of resistance to cisplatin.
Maria Kartalou,John M. Essigmann +1 more
TL;DR: An improved understanding of the mechanisms of resistance operative in vivo has identified targets for intervention and may increase the utility of cisplatin for the treatment of cancer.
Journal ArticleDOI
Recognition of cisplatin adducts by cellular proteins.
Maria Kartalou,John M. Essigmann +1 more
TL;DR: The structural information available for cisplatin and related platinumAdducts, the interactions of the adducts with cellular proteins and the implications of these interactions for cell survival are described.
Journal ArticleDOI
Advances in Platinum Chemotherapeutics
Benjamin W. J. Harper,Anwen M. Krause-Heuer,Maxine P. Grant,Madhura Manohar,K. Benjamin Garbutcheon-Singh,Janice R. Aldrich-Wright +5 more
TL;DR: Recent advances in the field of platinum chemotherapeutics are highlighted, with a focus on the technologies that attempt to utilise the cytotoxic nature of cisplatin, whilst improving drug targeting to reduce side-effects.
Journal ArticleDOI
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
TL;DR: It is shown that the human mismatch-repair protein, hMSH2, also binds specifically to DNA containing cisplatin adducts and displays selectivity for the DNAAdducts of therapeutically active platinum complexes.
Journal ArticleDOI
Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes.
TL;DR: Cisplatin and oxaliplatin both produce mainly 1,2‐GG intrastrand cross‐links as major adducts, but oxali Platin is found to be more active particularly against cisplatin‐resistant tumor cells, and mismatch repair and replicative bypass appear to be the processes most likely involved in differentiating the molecular responses to these two agents.